...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Comparison of Outcomes and Costs Associated With Aspirin +/- Clopidogrel After Coronary Artery Bypass Grafting
【24h】

Comparison of Outcomes and Costs Associated With Aspirin +/- Clopidogrel After Coronary Artery Bypass Grafting

机译：冠状动脉旁路嫁接后阿司匹林+/-氯吡格雷相关的结果和成本比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Optimal antiplatelet therapy after coronary artery bypass graft (CABG) surgery remains controversial. This study evaluated the role of dual antiplatelet therapy using aspirin and clopidogrel (DAPT) versus antiplatelet therapy using aspirin only (ASA) on post-CABG clinical outcomes and costs. In the Department of Veterans Affairs Randomized On/Off Bypass (ROOBY) trial, clopidogrel use after CABG was prospectively collected beginning in year 2 of this study to include 1,525 of the 2,203 original ROOBY patients who received aspirin after CABG. Discretionarily, surgeons after CABG administered either DAPT or ASA treatments. The ROOBY trial's primary 30-day composite (mortality or perioperative morbidity), 1-year composite (all-cause death, repeat revascularization, or nonfatal myocardial infarction), and costs were compared for these 2 strategies. Of the 1,525 subjects, 511 received DAPT and 1,014 received ASA. DAPT subjects, compared with ASA subjects, had lower rates of preoperative left ventricular ejection fraction of = 45% (78.8% vs 85.7%, p 0.001), on-pump CABG (36.6% vs 57.1%, p = 0.001), and endoscopic vein harvesting (30.0% vs 42.8%, p 0.001). ASA patients were more likely to have earlier aspirin administration and receive 325 versus 81 mg dosages. The 30-day composite outcome rate was significantly lower for DAPT patients compared with ASA patients (3.3% vs 7.1%, p = 0.003), but the 1-year composite outcome was equal between the 2 groups (12.0% vs12.0%, p = 1.0). At 1 year, there were no cost differences between the 2 groups. Propensity analyses did not significantly alter the results. In conclusion, DAPT appeared safe and was associated with fewer 30-day adverse outcomes than aspirin only and with no 1-year outcome or cost differences. Published by Elsevier Inc.
机译：冠状动脉旁路移植物（CABG）手术后最佳抗血小板治疗仍存在争议。该研究评估了双抗血小板治疗使用阿司匹林和氯吡格雷（DAPT）对抗血小板治疗使用阿司匹林（ASA）对CABG后临床结果和成本的作用。在退伍军人事务部随机开/关旁路（Rooby）试验中，在本研究的第2年开始，氯吡格雷使用在本研究的第2年度开始，包括1,525名在CABG之后接受阿司匹林的2,203名原始植物原患者。在CABG施用DAPT或ASA治疗后自由地，外科医生。罗比试验的主要30天复合（死亡率​​或围手术期发病率），1年复合物（终原死亡，重复血运重建或非致命性心肌梗死）以及对这2项策略进行了比较。在1,525名受试者中，511届收到DAPT和1,014个接受ASA。与ASA受试者相比的DAPT受试者具有较低的术前左心室喷射部分且GT; = 45％（78.8％Vs 85.7％，P <0.001），在泵车上（36.6％Vs 57.1％，P = 0.001 ），内窥镜静脉收获（30.0％Vs 42.8％，P <0.001）。 ASA患者更有可能具有早期的阿司匹林给药，并且接受325与81毫克剂量。与ASA患者相比，DAPT患者的30天复合结果率明显降低了（3.3％vs 7.1％，p = 0.003），但在2组之间，1年的复合结果平等（12.0％Vs12.0％， p = 1.0）。在1年，2组之间没有成本差异。倾向分析没有显着改变结果。总之，DATP似乎安全，与阿司匹林的30天不良结果有关，并且没有1年的结果或成本差异。 elsevier公司发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号